NIH Funded Research
BMC is a NIH FUNDED SITE for HIV and HCV Research
The Pediatric Infectious Disease group, combined with the Department of Obstetrics and the Adult HIV Program, has a well-established collaboration funded by NIH to address questions of national importance regarding HIV and HCV in pregnant women and their babies. Research studies targeting antiretroviral therapy of pregnant HIV infected women, prevention of vertical transmission, and early treatment of HIV infected newborns are ongoing.
In addition we have recently been awarded funding for research to identify risk factor in HCV infected pregnant women for vertical transmission of Hepatitis C. We have enrolled our first HCV infected mothers in this observational protocol and seek to enroll 200 women over the next 3 years. As well, with new therapeutic options available for adults, we plan future studies on early diagnosis of HCV in infants and potentially early treatment once HCV infection is confirmed.
Targeting HIV Infection:
Boston Medical Center is currently the only NIH funded member of the IMPAACT NETWORK (International Maternal, Pediatric, Adolescent, AIDS clinical trial network) in New England. The Network consists of domestic (US) and international clinical research sites conducting clinical trials important to the care and prevention of HIV infection in infants, children, adolescents, and pregnant women. Considered a Center of Excellence, we have been part of this important research network for over 25 years. BMC has been an active participant in the initial studies demonstrating interruption of the vertical transmission of HIV from mother to baby (with AZT and ‘076’ regimen, the initial studies of protease inhibitors (Ritonavir) in children, studies of immunogenicity and safety of vaccine in HIV infected children including pneumococcal and meningococcal vaccine, live attenuated influenza vaccine, varicella vaccine, etc. We offer to the latest state of the art therapeutics and diagnostics approaches. We are currently conducting research of investigational drugs and vaccines for both primary HIV therapy and the prevention and treatment of opportunistic infections and the long term complications of HIV infection.
In addition to the NIH funded clinical trials we have several ongoing industry sponsored trials, targeting the special population of children and adolescents such as those with multidrug resistant virus.
More information about the NIH agenda in HIV RESEARCH is also available at http://impaactnetwork.org/